axSpA

▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk for the UK and hpra.ie/homepage/about-us/report-an-issue for Republic of Ireland. Adverse events should also be reported to UCB Pharma Ltd at ucbcares.uk@ucb.com  or 0800 2793177 for the UK and UCB (Pharma) Ireland Ltd at ucbcares.ie@ucb.com or 1800 930075 for Republic of Ireland.

NICE image 02.jpg
BIMZELX DELIVERED HIGH TREATMENT TARGETS ACROSS THE FULL axSpA SPECTRUM1,2

BIMZELX® (bimekizumab) is indicated for the treatment of: active PsA, alone or in combination with methotrexate, in adults who have had an inadequate response or who have been intolerant to one or more DMARDs; active nr-axSpA, in adults with objective signs of inflammation as indicated by elevated CRP and/or MRI, who have responded inadequately or are intolerant to NSAIDs; and active AS, in adults who have responded inadequately or are intolerant to conventional therapy.2

EFFICACY
BIMZELX DELIVERED EFFICACY IN AXSPA PATIENTS, SUSTAINED OVER TIME (TO WEEK 104)4

 

In two pivotal phase Ill trials, 47.7% (n=61/128) of patients with nr-axSpA and 44.8% (n=99/221) of patients with AS achieved the primary endpoint of ASAS 40 at Week 16 with BIMZELX (vs 21.4% [n=27/126] and 22.5% [n=25/111] with placebo, respectively; p<0.001 in both trials)1,2

Symptom improvement
BIMZELX provided sustained efficacy (ASAS 40) consistently across the full axSpA spectrum to week 1641,2,6–11

Primary endpoint: ASAS 40 at Week 16 in both studies (p<0.001 versus placebo)6

These are two separate studies and should not be compared directly

 

Bimzelx_axSpA_Image 6.png
Bimzelx_axSpA_Image 7.png

To Week 164, 90.4% (519/574) of patients treated with BIMZELX had ≥1 TEAE. The most frequent TEAEs were COVID-19 (14.5 EAIR/100PY), nasopharyngitis (9.9 EAIR/100PY) and upper respiratory tract infection (5.8 EAIR/100PY).1

After Week 16, patients in BE MOBILE 1 and BE MOBILE 2 were aware that they were receiving active treatment, which may have affected the results. All patients, investigator site personnel, and operational staff employed by the sponsor remained blinded to the initial treatment group assignment until completion of the maintenance period at Week 52.7 

*In BE MOBILE 1, ASAS 40 was achieved by 16.4% (21/128) with BIMZELX at Week 1 (vs 1.6% (2/126] with placebo),7 47.7% [61/128] at Week 16 (vs [21.4% 27/126] with placebo; p<0.001), and 60.9% (78/128) at Week 52 of patients with nr-axSpA in the BIMZELX treatment arm (NRI analysis).6,9 In the open-label treatment period, ASAS 40 was achieved by 49.2% (125/254) of patients with nr-axSpA receiving BIMZELX at Week 104, and 48.4% (123/254) at Week 164 (NRI analysis).2,8 In BE MOBILE 2, ASAS 40 was achieved by 16.7% (37/221) with BIMZELX at Week 2 (vs 7.2% [8/111] with placebo),7 44.8% (99/221) at Week 16 (vs 22.5% [25/111] with placebo, p<0.001), and 58.4% (129/221) at Week 52 of patients with AS in the BIMZELX treatment arm (NRI analysis).6,9 In the open-label treatment period, ASAS 40 was achieved by 53.9% (179/332) of patients with AS receiving BIMZELX at Week 104, and 52.1% (173/332) at Week 164 (NRI analysis).2,8 In BE MOBILE 1, 86.6% (220/254) of patients with nr-axSpA remained on BIMZELX at Week 52.9 In BE MOBILE 2, 89.8% (298/332) of patients with AS remained on BIMZELX at Week 52.9**Included patients originally randomised to placebo.1

 

BIMZELX provided sustained ASAS 40 responses up to 5 years in the phase 2b open-label extension study in patients with AS12

 

Bimzelx_axSpA_Image 37.png

The BE AGILE study and its open-label extension were phase 2b studies12 The dose-ranging BE AGILE study consisted of a 12-week double-blind, placebo-controlled period, then a dose-blind period to Week 48 where patients with active AS received BIMZELX 160 mg or 320 mg Q4W. Patients completing Week 48 were eligible to enter the OLE where all patients received BIMZELX 160 mg Q4W to Week 256. Data presented here are for patients who received the licensed dose of BIMZELX 160 mg Q4W to Week 256. The long-term safety profile of BIMZELX in patients with AS was consistent with previous observations, with no new safety signals identified after five years of exposure.

After Week 16, all patients were aware that they were receiving active treatment, which may have affected the results.

*In BE AGILE, a phase 2b study in patients with AS, 97.7% (296/303) of patients entered the dose-blind period and 87.5% (265/303) completed Week 48 of treatment. 84.2% (255/303) then entered the OLE at Week 48 and received ≥1 dose of BIMZELX; 79.2% (202/255) of these patients completed 256 weeks of treatment.13 At Week 256, 49.7% of the NRI analysis dose-blind set (n=296), 59.0% of the NRI analysis OLE full-analysis set (n=249) and 73.1% of the OC analysis dose-blind set (n=201) achieved ASAS 40. In the NRI analysis, patients who did not enter the OLE period were recorded as non-responders from Week 48 to Week 256.12

With BIMZELX, ASAS 40 responses were maintained to 2 years across the full axSpA spectrum*14

 

Bimzelx_axSpA_Image 9.png

Efficacy outcomes are reported from the BE MOBILE 1 and 2 trials and combined open-label treatment period following Week 52 of BE MOBILE 1 and BE MOBILE 2 (BE MOVING). After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results.

*Pooled data from patients with nr-axSpA (BE MOBILE 1; n-128) and AS (BE MOBILE 2; n-221) randomised to BIMZELX 160 mg Q4W.6 At Week 16, ASAS 40 was achieved by 45.8% of patients with nr-axSpA or AS (160/349).14 Of those who achieved ASAS 40 at Week 16, 76.3% (n=122/160) maintained this response at Week 104 (NRI analysis).14

Reductions in disease activity
BIMZELX provided sustained reductions in disease activity up to 3 years across the full axSpA spectrum*1
Bimzelx_axSpA_Image 10.png

To Week 164, 90.4% (519/574) of patients treated with BIMZELX had ≥1 TEAE. The most frequent TEAEs were COVID-19 (14.5 EAIR/100PY), nasopharyngitis (9.9 EAIR/1OOPY) and upper respiratory tract infection (5.8 EAIR/1OOPY).1

After Week 16 all patients were aware that they were receiving active treatment. which may have affected the results.

*Pooled randomised set. Patients treated with BIMZELX 160 mg Q4W include patients originally randomised to placebo.1 In BE MOBILE 1, ASDAS <2 1 was achieved by 61.8% (157/254) of patients with nr-axSpA at Week 164.1 In BE MOBILE 2. ASDAS <2.1 was achieved by 59.9% (199/332) of patients with AS at Week 164.1 ASDAS disease states over time (MI analysis) were exploratory endpoints.6

 

Bimzelx_axSpA_Image 38.png

To Week 164, 90.4% (519/574) of patients treated with BIMZELX had ≥1 TEAE. The most frequent TEAEs were COVID-19 (14.5 EAIR/100PY), nasopharyngitis (9.9 EAIR/100PY) and upper respiratory tract infection (5.8 EAIR/100PY).1

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results.

*Pooled randomised set. Patients treated with BIMZELX 160 mg Q4W include patients originally randomised to placebo.1 In BE MOBILE 1, ASDAS <2.1 was achieved by 61.8% (157/254) of patients with nr-axSpA at Week 164.1 In BE MOBILE 2, ASDAS <2.1 was achieved by 59.9% (199/332) of patients with AS at Week 164.1 ASDAS disease states over time (MI analysis) were exploratory endpoints.6

 

With BIMZELX, reductions in disease activity were maintained up to 2 years across the full axSpA spectrum*14
Bimzelx_axSpA_Image 11.png

Efficacy outcomes are reported from the BE MOBILE 1 and 2 trials and combined open-label treatment period following Week 52 of BE MOBILE 1 and BE MOBILE 2 (BE MOVING}. After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results.

*Pooled data from patients with nr-axSpA (BE MOBILE 1; n =128) and AS (BE MOBILE 2; n=221) randomised to BIMZELX 160 mg Q4W.14 At Week 16, ASDAS <2.1 was achieved by 43.6% of patients with nr-axSpA or AS (NRI analysis; 152/349).14 Of those who achieved ASDAS-LDA at Week 16, 89.3% maintained this response at Week 104 (MI analysis; n number unavailable).14 At Week 16, ASDAS-ID was achieved by 16.6% of patients with nr-axSpA or AS (NRI analysis; 58/349).14 Of those who achieved ASDAS-ID at Week 16, 76.0% maintained this response at Week 104 (MI analysis; n number unavailable).14

 

Inflammation control
BIMZELX provided sustained reductions in MRI-detected inflammation across the full axSpA spectrum to Week 164*1,17

 

Bimzelx_axSpA_Image 12.png

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. 

*MRI sub-study enrolling patients receiving BIMZELX with baseline MRI SIJ SPARCC ≥2 (nr-axSpA; n=52) or baseline ASspiMRI-a Berlin score >2 (AS; n=31).17

Sustained suppression of inflammation (demonstrated by hs-CRP levels) was shown to Week 164 in patients treated with BIMZELX8

 

Bimzelx_axSpA_Image 13.png
Bimzelx_axSpA_Image 14.png

These are two separate studies and should not be compared directly. 

Adapted from UCB Data on file. 2024. AS0010 and AS0011. 3-Year Data Summary. p1-55.

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results.

*Manually calculated.8**Includes patients who were originally assigned to placebo.8

BIMZELX offered sustained resolution of peripheral arthritis (SJC=0)2

 

Bimzelx_axSpA_Image 15.png

*In patients with SJC>0 at baseline.2**At Week 16, 41.9% (n=18/43) and 36.4% (n=8/22) placebo-treated patients achieved SJC=0 in BE MOBILE 1 and BE MOBILE 2, respectively.9,18

†Pooled analysis. Includes patients originally randomised to placebo. 64.3% (n=99/154) of patients with baseline SJC>0 achieved total resolution of peripheral arthritis (SJC=0) with BIMZELX 160 mg Q4W at Week 104 (NRI analysis).2

Inhibition of disease progression
Minimal spinal radiographic progression (as measured by mSASSS) was demonstrated at Week 104 in AS patients treated with BIMZELX*4

 

Bimzelx_axSpA_Image 16.png

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. Non-progression was defined as mSASSS CfB of ≤0.5 or <2.0.

*Patients involved are from an X-ray sub-study with valid X-ray assessments at baseline and Week 104 (n=190). Mean absolute change in mSASSS from baseline (SD) was 0.3 (1.9) in patients with AS taking BIMZELX 160 mg Q4W at Week 104 (n=190); mean absolute mSASSS in patients with AS was 7.3 (13.8) at baseline and 7.6 (14.1) at Week 104 (OC analysis).4 mSASSS ranges from 0–72, with lower scores indicating less structural damage.4

Minimal spinal radiographic progression overall at Week 104 in patients with AS with BIMZELX4

 

Bimzelx_axSpA_Image 17.png

After Week 16 all patients were aware that they were receiving active treatment, which may have affected the results. Non-progression was defined as mSASSS CfB of ≤0.5 or <2.0.

*Patients involved are from an X-ray sub-study with valid X-ray assessments at baseline and Week 104 (n=190). Mean absolute change in mSASSS from baseline (SD) was 0.3 (1.9) in patients with AS taking BIMZELX 160 mg Q4W at Week 104 (n=190); mean absolute mSASSS in patients with AS was 7.3 (13.8) at baseline and 7.6 (14.1) at Week 104 (OC analysis).4 mSASSS ranges from 0–72, with lower scores indicating less structural damage.4 **Includes patients who were originally randomised to placebo.4,6,17

axspa-asdas-explained
Bimzelx
Bimzelx

Most common TEAES (>5.0% in BE MOBILE 1 and BE MOBILE 2) with BIMZELX across 52 weeks were:
• Nasopharyngitis (12.3%, n=30/244, and 9.1%, n=30/330), oral candidiasis (7.4%, n=18/244, and 6.1%, n=20/330), and URTIS (9.4%, n=23/244, and 6.4%, n=21/330) in BE MOBILE 1 and BE MOBILE 2, respectively3

 

Most frequent TEAEs to Week 104 by preferred term (EAIR/100 PY) were COVID-19 Infection (13.2), nasopharyngitis (10.2), and upper respiratory tract infection (6.0),22Most frequent TEAEs to Week 104 by preferred term (EAIR/100 PY)  were COVID-19 infection (13.2), nasopharayngitis (10.2), and upper respiratory tract infection (6.0).4


*Patient population is pooled and includes patients from both BE MOBILE 1 and BE MOBILE 2 who received a dose of BIMZELX, including those originally randomised to placebo, events are reported after switch only.4

Bimzelx

Most common TEAES (>5.0% in BE MOBILE 1 and BE MOBILE 2) with BIMZELX across 52 weeks were:
• Nasopharyngitis (12.3%, n=30/244, and 9.1%, n=30/330), oral candidiasis (7.4%, n=18/244, and 6.1%, n=20/330), and URTIS (9.4%, n=23/244, and 6.4%, n=21/330) in BE MOBILE 1 and BE MOBILE 2, respectively3

 

Most frequent TEAEs to Week 104 by preferred term (EAIR/100 PY) were COVID-19 Infection (13.2), nasopharyngitis (10.2), and upper respiratory tract infection (6.0),22Most frequent TEAEs to Week 104 by preferred term (EAIR/100 PY)  were COVID-19 infection (13.2), nasopharayngitis (10.2), and upper respiratory tract infection (6.0).4


*Patient population is pooled and includes patients from both BE MOBILE 1 and BE MOBILE 2 who received a dose of BIMZELX, including those originally randomised to placebo, events are reported after switch only.4

Skip to main content Toolbar items Manage Administration menu Tools Content Structure Appearance Extend Configuration Translation People Reports Help HCP User Guide Vertical orientation Shortcuts Panduro Elizabeth (External) Search Admin Toolbar quick search Preview Breadcrumb Home Edit Image axSpA image 13.png Add to Default shortcuts Primary tabs Edit(active tab) Delete Revisions Clone Name axSpA image 13.png Image Image axSpA image 13.png (36.95 KB) Alternative text Bimzelx Short description of the imag
How to use
SIMPLICITY 2

 

BIMZELX is administered as a single 160 mg subcutaneous injection once every 4 weeks*2

dose
INJECTION CHART

*The recommended dose for adult patients with axial spondyloarthritis is 160 mg (given as one subcutaneous injection) every four weeks. Consideration should be given to discontinuing treatment in patients who have shown no improvement by 16 weeks of treatment.2

Pivotal phase III study design: BE MOBILE 1
 
Patients with nr-axSpA (TNFi-naïve and TNFi-inadequate responders)9
Be Mobile

Adapted from van der Heijde D, et al. Ann Rheum Dis. 2023; 82(4):515-526. Supplementary appendix.

Pivotal phase III study design: BE MOBILE 2

Patients with AS (TNFi-naïve and TNFi-inadequate responders)9
Be Mobile 2

Adapted from van der Heijde D, et al. Ann Rheum Dis. 2023; 82(4):515-526. Supplementary appendix.

Phase IIb and open-label extension study design: BE AGILE

Patients with AS19
Be agile

Adapted from Baraliakos X, et al. Arthritis Rheumatol. 2022; 71(q12): 1943-58. Supplementary Appendix.

Abbreviations

AE, adverse event; ALT, alanine aminotransferase; AS, ankylosing spondylitis; ASAS 20/40, ≥20/40% Improvement in the Assessment of SpondyloArthritis international Society criteria; ASAS-PR, Assessment of SpondyloArthritis international Society criteria-Partial Remission; ASDAS, Ankylosing Spondylitis Disease Activity Score; ASDAS-CII, Ankylosing Spondylitis Disease Activity Score showing clinically important improvement; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score using CRP; ASDAS-ID, Ankylosing Spondylitis Disease Activity Score-inactive disease; ASDAS-LDA, Ankylosing Spondylitis Disease Activity Score-low disease activity; ASDAS-MI, Ankylosing Spondylitis Disease Activity Score-major improvement; ASQoL, Ankylosing Spondylitis Quality of Life; ASspiMRI, ankylosing spondylitis spinal magnetic resonance imaging; AST, aspartate aminotransferase; axSpA, axial spondyloarthritis; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASDAI 50, ≥50% response in the Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BKZ, bimekizumab; CfB, change from baseline; CI, Confidence Interval; COVID-19, Coronavirus Disease 2019; CRP, C-reactive protein; DBS, dose-blind set; DMARD, disease-modifying antirheumatic drug; EAIR, exposure-adjusted event rate; EULAR, European Alliance of Associations for Rheumatology; FACIT-F, Functional Assessment of Chronic Illness Therapy – Fatigue; FAS, Fetal Alcohol Syndrome; HLT, Heart-Lung Transplantation; hs-CRP, high sensitivity C-reactive protein; IBD, inflammatory bowel disease; ID, inactive disease; IL, interleukin; MACE, major adverse cardiovascular event; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; MedDRA, Medical Dictionary for Regulatory Activities; MI, multiple imputation; MRI, magnetic resonance imaging; mNRI, Masgutova Neurosensorimotor Reflex Integration; MRI SPARCC, SpondyloArthritis Research Consortium of Canada MRI score; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; NEC, Necrotizing Enterocolitis; NMSC, Non-melanoma Skin Cancer; nr-axSpA, non-radiographic axial spondyloarthritis; NRI, non-responder imputation; NSAID, non-steroidal anti-inflammatory drug; OC, observed case; OLE, open-label extension; OR, odds ratio; OSI, objective signs of inflammation; PRO, patient-reported outcome; PsA, psoriatic arthritis; PY, patient-years; Q2/4/6/8/12W, every 2/4/6/8/12 weeks; QoL, quality of life; SD, standard deviation; SF-36, Short-Form 36-item Health Survey; SF-36 PCS, Short Form-36 Physical Component Summary; SFU, Society for Fetal Urology; SIB, suicidal ideation and behaviour; SIJ, sacroiliac joints; SJC, swollen joint count; SmPC, Summary of Product Characteristics; SMQ, Standardised MedDRA Query; SOC, System Organ Class; SPARCC, SPondyloArthritis Research Consortium of Canada; TEAE, treatment-emergent adverse event; TNFi- naïve, TNF inhibitor-naive; TNFi-IR, tumour necrosis factor inhibitor-inadequate responder; ULN, upper limit of normal; WPAI:axSpa, Work Productivity and Activity Impairment Questionnaire - Specific Health Problem.

References

  1. Baraliakos, X., Deodhar, A., van der Heijde, D., van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Voiniciuc, D., Prajapati, C., Manente, M., Marten, A., & Gensler, L. S. (2025). Pos0788 bimekizumab demonstrated sustained efficacy and safety across the full spectrum of axial spondyloarthritis: 3-year results from two phase 3 studies and their open-label extension. EULAR. Poster POS0788.
  2. Baraliakos, X., Deodhar, A., van der Heijde, D., Van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Vaux, T., Prajapati, C., Manente, M., Marten, A., & Gensler, L. S. (2025). Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies. Rheumatology (Oxford, England), 64(6), 3534–3546.
  3. Gensler, L. S., Marzo-Ortega, H., Taieb, V., Voiniciuc, D., Marten, A., Stojan, G., Kim, M., & Rudwaleit, M. (2024). Achievement of Remission Defined by Abscence of Objective Signs of Inflammation versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies. American College of Rheumatology.
  4. Baraliakos, X., Ramiro, S., Maksymowych, W., Ostergaard, M., Massow, U., Vaux, T., Prajapati, C., Marten, A., de Peyrecave, N., & Poddubnyy, D. (2024). Minimal Spinal Radiographic Progression in Patients with Radiographic Axial Spondyloarthritis over 2 Years of Bimekizumab Treatment: Results from a Phase 3 Open-Label Extension Study. American College of Rheumatology.
  5. Navarro-Compán, V., Kiltz, U., Mease, P. J., Dubreuil, M., Gaffney, K., Deodhar, A., de la Loge, C., Voiniciuc, D., Coarse, J., & Marzo-Ortega, H. (2025). Pos0921 sustained improvements with bimekizumab in pain, morning stiffness, fatigue, physical function and health-related quality of life in patients with axial spondyloarthritis: 3-year results from two phase 3 studies. EULAR.
  6. van der Heijde, D., Deodhar, A., Baraliakos, X., Brown, M. A., Dobashi, H., Dougados, M., Elewaut, D., Ellis, A. M., Fleurinck, C., Gaffney, K., Gensler, L. S., Haroon, N., Magrey, M., Maksymowych, W. P., Marten, A., Massow, U., Oortgiesen, M., Poddubnyy, D., Rudwaleit, M., … Xu, H. (2023). Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the Rheumatic Diseases, 82(4), 515–526.
  7. UCB Pharma Limited. (2025). Bimzelx - Summary of Product Characteristics. Medicines.org.uk. https://www.medicines.org.uk/emc/product/12833/smpc
  8. UCB. (2023). AS0010 and AS0011. 3-Year Data Summary. p1-55. UCB Data on File.
  9. Baraliakos, X., Deodhar, A., van der Heijde, D., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Fleurinck, C., Ellis, A. M., Vaux, T., Shepherd-Smith, J., Marten, A., & Gensler, L. S. (2024). Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Annals of the Rheumatic Diseases, 83(2), 199–213.
  10. Baraliakos, X., Deodhar, A., van der Heijde, D., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Fleurinck, C., Ellis, A. M., Vaux, T., Shepherd-Smith, J., Marten, A., & Gensler, L. S. (2024). Bimekizumab treatment in patients with active axial spondyloarthritis: 52-week efficacy and safety from the randomised parallel phase 3 BE MOBILE 1 and BE MOBILE 2 studies. Annals of the Rheumatic Diseases, 83(2), 199-213. Supplementary Appendix.
  11. UCB. (2023). AS0010/AS0011/AS0014. Table BKZ_AS2024_041_001_01. UCB Data on File.
  12. Deodhar, A., Navarro-Compán, V., Poddubnyy, D., Gensler, L. S., Ramiro, S., Tomita, T., Marzo-Ortega, H., Fleurinck, C., Vaux, T., Massow, U., de Peyrecave, N., van der Heijde, D., & Baraliakos, X. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open, 11(1), e005081.
  13. Deodhar, A., Navarro-Compán, V., Poddubnyy, D., Gensler, L. S., Ramiro, S., Tomita, T., Marzo-Ortega, H., Fleurinck, C., Vaux, T., Massow, U., de Peyrecave, N., van der Heijde, D., & Baraliakos, X. (2025). Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension. RMD Open, 11(1), e005081. Supplementary Appendix.
  14. Proft, F., van der Heijde, D., Schwartzman, S., Ermann, J., Marten, A., Massow, U., Stojan, G., Taieb, V., Voiniciuc, D., van Tubergen, A., Navarro Compán, V., & Baraliakos, X. (2024). Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies. American College of Rheumatology.
  15. Aranda-Valera, I. C., Garrido-Castro, J. L., Ladehesa-Pineda, L., Vazquez-Mellado, J., Zarco, P., Juanola, X., Gonzalez-Navas, C., Font-Ugalde, P., & Castro-Villegas, M. C. (2020). How to calculate the ASDAS based on C-reactive protein without individual questions from the BASDAI: the BASDAI-based ASDAS formula. Rheumatology (Oxford, England), 59(7), 1545–1549.
  16. Zochling, J. (2011). Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing spondylitis disease activity score (ASDAS), ankylosing spondylitis quality of life scale (ASQoL), bath ankylosing spondylitis disease activity index (BASDAI), bath ankylosing spondylitis functional index (BASFI), bath ankylosing spondylitis global score (BAS-G), bath ankylosing spondylitis metrology index (BASMI), dougados functional index (DFI), and health assessment questionnaire for the spondylarthropathies (HAQ-S). Arthritis Care & Research, 63 Suppl 11(S11), S47-58.
  17. Baraliakos, X., Deodhar, A., Van der Heijde, D., Van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Fleurinck, C., Vaux, T., Prajapati, C., Shepherd-Smith, J., Marten, A., & Gensler, L. S. (2024). Pos0806 long-term sustained efficacy and safety of bimekizumab across the full spectrum of axial spondyloarthritis: 2-year results from two phase 3 studies. EULAR.
  18. van der Heijde, D., Deodhar, A., Baraliakos, X., Brown, M. A., Dobashi, H., Dougados, M., Elewaut, D., Ellis, A. M., Fleurinck, C., Gaffney, K., Gensler, L. S., Haroon, N., Magrey, M., Maksymowych, W. P., Marten, A., Massow, U., Oortgiesen, M., Poddubnyy, D., Rudwaleit, M., … Xu, H. (2023). Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials. Annals of the Rheumatic Diseases, 82(4), 515-526. Supplementary Appendix.
  19. Marzo-Ortega, H., Mease, P., Dougados, M., Dubreuil, M., Magrey, M., Rudwaleit, M., D’Agostino, M. A., de la Loge, C., Massow, U., Taieb, V., Voiniciuc, D., & Deodhar, A. (2024). Sustained Improvements with Bimekizumab in Patient-Reported Symptoms of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies. American College of Rheumatology.
  20. Dubreuil, M., Navarro-Compán, V., Boonen, A., Gaffney, K., Gensler, L. S., de la Loge, C., Vaux, T., Fleurinck, C., Massow, U., Taieb, V., Mørup, M. F., Deodhar, A., & Rudwaleit, M. (2024). Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies. RMD Open, 10(2), e004202.
  21. Navarro-Compán, V., Dubreuil, M., Gaffney, K., Kay, J., de la Loge, C., Massow, U., Taieb, V., Vaux, T., & Deodhar, A. (2024). Sustained Improvements with Bimekizumab in Spinal Mobility, Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies. American College of Rheumatology.
  22. Baraliakos, X., Deodhar, A., van der Heijde, D., Van den Bosch, F., Magrey, M., Maksymowych, W. P., Tomita, T., Xu, H., Massow, U., Vaux, T., Prajapati, C., Manente, M., Marten, A., & Gensler, L. S. (2025). Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies. Rheumatology (Oxford, England), 64(6), 3534-3546. Supplementary Appendix.
  23. Garrett, S., Jenkinson, T., Kennedy, L. G., Whitelock, H., Gaisford, P., & Calin, A. (1994). A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology, 21(12), 2286–2291.
  24. Ankylosing Spondylitis (Axial Spondyloarthritis) (AS). The Bath Indices. (n.d.). National Axial Spondyloarthritis Society. Retrieved 22 September 2025, from https://nass.co.uk/wp-content/uploads/2018/09/Bath-Indices.pdf
  25. Baraliakos, X., Ramiro, S., Magrey, M., Rudwaleit, M., Haroon, N., Fleurinck, C., Massow, U., De Peyrecave, N., Vaux, T., Marzo-Ortega, H., & Navarro-Compán, V. (2023). Pos1106 achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: Results from the phase 3 studies be mobile 1 and be mobile 2. Scientific Abstracts, 82, 875–876.
  26. Mease, P. J., Gensler, L. S., Orbai, A.-M., Warren, R. B., Bajracharya, R., Ink, B., Marten, A., Massow, U., Shende, V., Manente, M., Peterson, L., White, K., Landewé, R., & Poddubnyy, D. (2025). Long-term safety of bimekizumab in adult patients with axial spondyloarthritis or psoriatic arthritis: pooled results from integrated phase IIb/III clinical studies. RMD Open, 11(2), e005026.
  27. Rudwaleit, M., Brown, M., Van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., Massow, U., De Peyrecave, N., Vaux, T., White, K., Deodhar, A., & Van der Horst-Bruinsma, I. (2023). Pos0668 low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: Pooled results from phase 2b/3 trials. 82(Suppl 1), EULAR.
  28. Brown, M. A., Rudwaleit, M., van Gaalen, F. A., Haroon, N., Gensler, L. S., Fleurinck, C., Marten, A., Massow, U., de Peyrecave, N., Vaux, T., White, K., Deodhar, A., & van der Horst-Bruinsma, I. (2024). Low uveitis rates in patients with axial spondyloarthritis treated with bimekizumab: pooled results from phase 2b/3 trials. Annals of the Rheumatic Diseases, 83(12), 1722–1730.
  29. van der Horst-Bruinsma, I. E., Brown, M. A., van Gaalen, F., Haroon, N., Gensler, L. S., Marten, A., Manente, M., Stojan, G., Vaux, T., White, K., Deodhar, A., & Rudwaleit, M. (2024, September 1). Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials. ACR Meeting Abstracts. https://acrabstracts.org/abstract/low-uveitis-rates-in-patients-with-axial-spondyloarthritis-or-psoriatic-arthritis-treated-with-bimekizumab-long-term-results-from-phase-2b-3-trials/
  30. Baraliakos, X., Deodhar, A., Dougados, M., Gensler, L. S., Molto, A., Ramiro, S., Kivitz, A. J., Poddubnyy, D., Oortgiesen, M., Vaux, T., Fleurinck, C., Shepherd-Smith, J., de la Loge, C., de Peyrecave, N., & van der Heijde, D. (2022). Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: Three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis & Rheumatology, 74(12), 1943–1958.
  31. Baraliakos, X., Deodhar, A., Dougados, M., Gensler, L. S., Molto, A., Ramiro, S., Kivitz, A. J., Poddubnyy, D., Oortgiesen, M., Vaux, T., Fleurinck, C., Shepherd-Smith, J., de la Loge, C., de Peyrecave, N., & van der Heijde, D. (2022). Safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: Three-year results from a phase IIb randomized controlled trial and its open-label extension study. Arthritis & Rheumatology, 74(12), 1943-1958. Supplementary Appendix.
logo

IE-BK-2400125

Date of creation: September 2024